MICHAEL J. DETKE

Michael J. Detke, MD, PhD
President, Detke Biopharma Consulting LLC
Clinical Professor of Psychiatry, Indiana University School of Medicine

Mike Detke is a board-certified psychiatrist with over 25 years of research experience and extensive clinical and drug development expertise. He is founder and president of Detke Biopharma Consulting LLC, in which he consults Pharma, biotech, and NIH regarding CNS drug development and business strategy, mostly in C-level leadership roles. He provides medical leadership on clinical development, clinical trial design and conduct, regulatory documents such as INDs and Fast-Track applications, and at FDA meetings.

Dr. Detke was MedAvante CMO from 2009-2013, where he led a team dedicated to researching and improving signal detection in CNS clinical trials, collaborating with many CNS biotech and pharmaceutical companies. With Eli Lilly from 2000-2009, Dr. Detke oversaw CNS assets in early phase development, including all psychiatric, neurological, and pain indications. Previous Lilly roles included general management of large teams of physicians/scientists and budgetary responsibilities.

Since 2000, Dr. Detke teaches and supervises medical students and residents in patient care as a volunteer (adjunct) Clinical Professor of Psychiatry at Indiana University School of Medicine. Graduating summa cum laude with a BA and MS in Psychology at Yale University, he later received his MA, MD, and PhD degrees at the University of Pennsylvania. His training in psychiatry was conducted at Harvard Medical School, McLean and Massachusetts General Hospitals. He has published over 70 manuscripts in peer-reviewed journals, serves as a reviewer for numerous such journals, and is an active member of selective scientific organizations such as ACNP, ASCP, ISCTM and SOBP.